Thompson Siegel & Walmsley LLC Trims Stock Position in Organon & Co. (NYSE:OGN)

Thompson Siegel & Walmsley LLC lessened its holdings in shares of Organon & Co. (NYSE:OGN) by 90.8% in the 4th quarter, HoldingsChannel reports. The firm owned 208,808 shares of the company’s stock after selling 2,053,571 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Organon & Co. were worth $3,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Pacer Advisors Inc. raised its holdings in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Organon & Co. by 2.0% during the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after purchasing an additional 82,220 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Organon & Co. by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock worth $49,739,000 after purchasing an additional 10,652 shares during the last quarter. Private Management Group Inc. raised its holdings in shares of Organon & Co. by 11.9% during the fourth quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock worth $31,620,000 after purchasing an additional 225,420 shares during the last quarter. Finally, Weiss Asset Management LP purchased a new position in shares of Organon & Co. during the third quarter worth $32,966,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley dropped their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. Finally, Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Stock Down 0.2 %

OGN stock opened at $14.97 on Friday. The firm has a market cap of $3.86 billion, a PE ratio of 4.49, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm’s fifty day moving average is $15.46 and its 200 day moving average is $16.78. Organon & Co. has a one year low of $13.87 and a one year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.48%. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.